Compare BR & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BR | NBIX |
|---|---|---|
| Founded | 1962 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7B | 15.5B |
| IPO Year | 2006 | 1996 |
| Metric | BR | NBIX |
|---|---|---|
| Price | $180.85 | $145.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 29 |
| Target Price | ★ $213.38 | $206.22 |
| AVG Volume (30 Days) | 652.8K | ★ 1.2M |
| Earning Date | 11-03-2026 | 11-02-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | 35.21 | ★ 41.95 |
| EPS | ★ 9.60 | 3.30 |
| Revenue | ★ $4,142,600,000.00 | $161,626,000.00 |
| Revenue This Year | $5.06 | $36.49 |
| Revenue Next Year | $4.94 | $16.87 |
| P/E Ratio | ★ $19.02 | $43.24 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $133.83 | $122.14 |
| 52 Week High | $233.10 | $186.12 |
| Indicator | BR | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 65.73 | 54.60 |
| Support Level | $164.21 | $125.18 |
| Resistance Level | $186.91 | $146.92 |
| Average True Range (ATR) | 3.56 | 3.14 |
| MACD | 1.99 | 1.20 |
| Stochastic Oscillator | 82.46 | 96.43 |
Broadridge Financial Solutions, which was spun off from Automatic Data Processing in 2007, is a leading provider of investor communication and technology-driven solutions to banks, broker/dealers, traditional and alternative-asset managers, wealth managers, and corporate issuers. Broadridge is composed of two operating segments: investor communication solutions and global technology and operations.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.